Pharmacovigilance Global Market Report: Industry Trends and Key Developments | 2024 To 2033 Key Players IQVIA, Cognizant, ICON Plc, PAREXEL International Corporation., United BioSource LLC.

The Business Research Company recently released a comprehensive report on the Global Pharmacovigilance Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

According to The Business Research Company's, The pharmacovigilance market size has grown rapidly in recent years. It will grow from $7.63 billion in 2023 to $8.67 billion in 2024 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing incidence of adverse drug reactions (adrs), the increasing research and development (r&d) activities, the growing drug development rates, the increasing focus on personalized medicine and the rising prevalence of chronic diseases.

The pharmacovigilance market size is expected to see rapid growth in the next few years. It will grow to $14.11 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to the rising healthcare expenditure, the increasing government support and the aging population. Major trends in the forecast period include increasing investments, use of artificial intelligence, use of innovative platforms, use of innovative cloud-based systems and strategic mergers and acquisitions.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Market Drivers and Trends:

The increasing research and development activities will drive the pharmacovigilance market. By investing in R&D, pharmaceutical companies can develop new and innovative drugs with improved safety profiles. Rigorous preclinical and clinical testing during the drug development process enables early identification of potential safety concerns, allowing for appropriate risk mitigation strategies to be implemented. Additionally, R&D efforts contribute to the advancement of technologies for adverse event monitoring, data analysis, and signal detection, facilitating the early detection of adverse drug reactions in the post-marketing phase. For example, in February 2022, according to a study issued by IQVIA, a US-based supplier of biopharmaceutical development and commercial outsourcing services, venture capital deal activity and the flow of investments in the United States have increased in the last two years as demand in life sciences has increased, with over 2,000 agreements and $47 billion in deal value expected in 2021. Furthermore, the 15 top pharmaceutical corporations would invest a record $133 billion in R&D in 2021, a 44% increase over prior years. Furthermore, the total number of research participants in planned new trials will surpass 2 million in 2021, more than double the quantity seen before the research. Therefore, the increasing research and development activities supported the growth of the pharmacovigilance market.

Companies in the pharmacovigilance market are focusing on artificial intelligence (AI) to improve efficiency. AI can help improve the efficiency and accuracy of pharmacovigilance activities, ultimately leading to better patient outcomes. By utilizing AI, pharma companies can streamline their processes, improve data management, and accelerate drug discovery, while simultaneously reducing costs and improving safety. For example, in November 2021, Deloitte, a UK-based professional services company, and Sanofi, a France-based company that is responsible for managing pharmacovigilance tasks and activities worldwide, collaborated on a next-generation, artificial intelligence (AI) software-as-a-service adverse events case intake platform called ConvergeHEALTH Safety™, to modernize pharmacovigilance (PV) and tackle some of the major operational issues facing the sector. As a result of the initial deployment, Sanofi has already increased case quality and processing efficiency within PV by automating the case intake process. This has allowed Sanofi to concentrate resources on the remainder of the adverse event (AE) case process as well as on optimizing the benefit-risk profiles of their medications.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Inogen Inc, Koninklijke Philips N.V, Teijin Limited, Invacare Corporation, CAIRE Inc, O2 Concepts LLC, Nidek Medical Products Inc., Precision Medical Inc, Drive Devilbiss Healthcare Ltd, 3B Medical Inc, BPL, Eloxy Technology, Evox Oxygen Concentrators, Nanjing Everich Medicare Import & Export Co. Ltd, AngelBiss Medical Technology Co. Ltd, Hefei DX Medical Co. Ltd, Longfian Scitech Co. Ltd, Yokogawa United Kingdom Ltd, Noxerior, Air Liquide Sanita Service, Pure O2, Heinen + Lowenstein GmbH & Co. KG, DeVilbiss Healthcare GmbH, NGK Spark Plug Co. Ltd, Chart Industries Inc, White Martins, 3M Company, Pfizer, Baxter, Novartis, Johnson &Johnson, Bayer, GlaxoSmithKline, B Braun, Boehringer Ingelheim, Sanofi, Merck Group, West Pharmaceutical, Allergan, Catalent, Bilim Pharmaceuticals, H&T Press part, Hovione Technology, Sorrel Medical, Syqe Medical, Julphar, Novo Nordisk, Abbott Laboratories, Becton Dickinson, Siemens, Medtronic, Roche, Supera Anaesthesia Innovations, Linde Plc, ResMed

Pharmacovigilance Market 2024 Key Insights:

• The pharmacovigilance market size is expected to see rapid growth in the next few years. It will grow to $14.11 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%.
• Research And Development Drive Growth In The Pharmacovigilance Market
• Pharmacovigilance Market Embraces Artificial Intelligence For Enhanced Efficiency And Safety
• North America was the largest region in the pharmacovigilance market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=5928&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.